FHIR IG analytics

Resources that use this resource

No resources found

Resources that this resource uses

No resources found

Narrative

Note: links and images are rebased to the (stated) source

Source1

{
  "resourceType": "MedicationRequest",
  "id": "mii-exa-onko-cdk46-class-medication",
  "meta": {
    "profile": [
      "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/StructureDefinition/mii-pr-onko-therapieempfehlung-medikation|2027.0.0-ballot.1"
    ]
  },
  "text": {
    "status": "generated",
    "div": "<!-- snip (see above) -->"
  },
  "status": "active",
  "intent": "option",
  "medicationCodeableConcept": {
    "coding": [
      {
        "system": "http://fhir.de/CodeSystem/bfarm/atc",
        "code": "L01EF",
        "display": "Cyclin-abhängige Kinasen (CDK)-Inhibitoren"
      }
    ],
    "text": "CDK4/6 Inhibitor (Klasse L01EF) - Palbociclib, Ribociclib oder Abemaciclib"
  },
  "subject": {
    "reference": "Patient/mii-exa-onko-molecular-board-patient"
  },
  "authoredOn": "2024-01-15",
  "reasonReference": [
    {
      "reference": "Condition/primaertumor-example"
    }
  ],
  "note": [
    {
      "text": "Molekulares Tumorboard empfiehlt beliebigen CDK4/6 Inhibitor basierend auf HR+/HER2- Profil. Konkrete Wirkstoffauswahl nach Verfügbarkeit und Patientenfaktoren."
    }
  ]
}